FSTX F-star Therapeutics, Inc.

F-star is a clinical-stage biopharmaceutical company with an advanced pipeline of multiple immuno-oncology programs dedicated to creating a paradigm-shift in cancer therapy.

As of 12/03/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/06/2016
Outstanding shares:  20,624,494
Average volume:  266,008
Market cap:   $107,453,614
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    30315R107
ISIN:        US30315R1077
Valuation   (See tab for details)
PE ratio:   -2.43
PB ratio:   1.13
PS ratio:   4.10
Return on equity:   -86.23%
Net income %:   -296.71%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy